Daratumumab (Darzalex®) for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
NCPE Assessment Process | Complete |
Rapid review commissioned | 09/10/17 |
Rapid review completed | 27/11/17 |
Rapid Review Outcome | A full pharmacoeconomic evaluation is recommended. |
Full pharmacoeconomic assessment commissioned by HSE | 29/11/2017 |
Pre-submission consultation with Applicant | 23/01/2018 |
Submission received from Applicant | 21/09/2018 |
Preliminary review sent to Applicant | 30/11/2018 |
NCPE assessment re-commenced | 20/12/2018 |
Factual accuracy sent to Applicant | 05/02/2019 |
NCPE assessment re-commenced | 13/02/2019 |
Current Status | NCPE assessment ongoing |